-
Evaluating the Efficacy of a Psychedelic Investigational Drug for Patients who are Struggling with Symptoms of Depression and Anxiety due to Cancer or Other Life-Changing Medical Illness
Official Title A Randomized, Double-Blind, Parallel-Group, Dose-Controlled Study Evaluating the Safety and Efficacy of RE104 for Injection in the Treatment of Adjustment Disorder in Patients with Cancer and Other Medical IllnessesPurpose
The purpose of this study is to determine if treatment with a single dose of RE104 for Injection reduces depressive symptoms or depressive symptoms mixed with anxiety symptoms in participants with Adjustment Disorder due to cancer or other illnesses such as Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), Parkinson's Disease (PD) or Idiopathic Pulmonary Fibrosis (IPF) as compared to active-placebo.
Could this study be right for you?
- Depression due to cancer, Parkinson’s, ALS, MS, or IPF
- Currently depressed
- Projected life expectancy of ≥6 months.
Age Range
18 - 80 years -
Evaluating the Safety and Efficacy of Icalcaprant in the Treatment of Subjects with Major Depressive Disorder (MDD)
Official Title A Phase 2, Multicenter, 6-Week, Double Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Icalcaprant in Subjects with Major Depressive DisorderPurpose
Major depressive disorder (MDD; depression) is a mood disorder that causes a continued feeling of sadness and loss of interest. It is a common and serious illness that can cause both emotional and physical symptoms such as feelings of sadness, irritability, not being able to focus on activities, tiredness, changes in eating habits, and aches and pains.
This study will assess the changes in disease activity and adverse events of oral Icalcaprant in adult participants with major depressive disorder who are currently experiencing a major depressive episode (MDE).
Could this study be right for you?
- Diagnosed with MDD
- Current major depressive episode
- Willing to discontinue antidepressant treatments
Age Range
18 - 65 years -
Evaluating the Efficacy and Safety of Icalcaprant in Subjects with Bipolar Depression
Official Title A Phase 2, Multicenter, 6-Week, Double Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Icalcaprant in Subjects with Bipolar DepressionPurpose
Bipolar disorder is a severe chronic mood disorder that affects up to 4% of the adult population.This study will assess how safe and effective Icalcaprant is in treating adult participants with bipolar I or II disorder.
Could this study be right for you?
- Diagnosed with Bipolar Disorder I or II
- Currently in a depressive episode
- Currently receiving treatment of a mood stabilizer
Age Range
18 - 65 years -
Generalized Anxiety Disorder Study for Those Who Have Had an Inadequate Response to Antidepressants
Official Title A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dose Study to Evaluate the Efficacy, Safety, and Tolerability of ABBV-932 as an Adjunct to Antidepressant Therapies in the Treatment of Subjects With Generalized Anxiety Disorder Who Have Had an Inadequate Response to Antidepressant TherapiesPurpose
Generalized anxiety disorder (GAD) is usually treated with antidepressant therapy (ADT); however, sometimes ADTs alone are not enough to adequately treat GAD. The purpose of this study is to assess how safe and effective ABBV-932 is when added to the antidepressant therapies in adult participants with GAD who have had an inadequate response ADTs.
Could this study be right for you?
- Adults 18-65
- Diagnosed with GAD
- No depressive episodes in at least 6 months
- Currently receiving treatment of either paroxetine, escitalopram, duloxetine, or venlafaxine ER
Age Range
18 - 65 years -
Emotions, Stress, and Mental Health
Official Title Emotions and Stress StudyPurpose
We are conducting a study to learn about the ways that adults cope with different types of stress in daily life. If you choose to participate in this study, you will be asked to answer a few questions to determine if you are a good fit for the study.
If you are a good fit for the study, you will attend a virtual meeting with a researcher, complete 2 questionnaires about your emotions and coping strategies, and complete short surveys multiple times per day for one week. This virtual meeting and first questionnaire will take about 1 hour to complete. The short surveys will take about 2-5 minutes to complete. The last questionnaire will take about 30 minutes to complete. The final questionnaire will take no longer than an hour to complete.
This entire study will last up to 5.5 hours total.
Could this study be right for you?
Individuals who identify as Black or African American.
Age Range
18 years and up -
Living Well with Advanced Breast Cancer
Official Title Living Well with Advanced Breast CancerPurpose
The purpose of this study is to understand how patients with advanced breast cancer are using supportive care, what has helped them, what has been hard, and what kind of help they still need. Our goal is to learn from patients and caregivers about met and unmet survivorship care needs, including care that focuses on improving health and well-being of a person living with cancer.
Study participants would be asked to complete a brief survey on their demographics via phone or email. Participants will then complete a one-time interview with our study staff via zoom, phone call, or in person, depending on preference. During the interview, the study team will ask for feedback on patient and caregiver experience and needs regarding support services.
Total study participation is less than 2 hours and can be done remotely.
Could this study be right for you?
- Diagnosed with stage 4 metastatic breast cancer within the past 5 years
- A patient in the Medical Oncology Clinic at Stephanie Spielman Comprehensive Breast Center (SSCBC)
Age Range
18 - 110 years -
MARIS Study for Young Girls
Official Title Longitudinal Modeling of Interpersonal Stress Induced Rumination to Understand Depression Risk in Adolescent Girls (MARIS)Purpose
This study looks at how young girls think about and react to stress—both in their brains and in their daily lives—to see how these patterns might lead to or predict depression. It aims to understand whether certain ways of handling stress put some girls at higher risk for developing depressive symptoms.
If eligible, the child will complete assessments which include clinical interviews over Zoom, surveys, cognitive testing, and an MRI each year, for up to three years.
A parent/guardian is required to enroll in the study and will complete questionnaires and a clinical interview as well.
Could this study be right for you?
Inclusion Criteria:
- Female
- 10-14 years of age at enrollment
- Youth assent and parent consent
Exclusion Criteria:
- Psychotropic medication use in the past 4 months
- Metal braces or plans for braces in the next 2 years
- Developmental disorder
- History or diagnosis of depression, substance use disorder, bipolar disorder, psychosis or seizures
- Traumatic brain injury
- Claustrophobia
Age Range
10 - 14 years -
Blocking Orexin Receptors to Help Treat Alcohol Addiction and Stress-Driven Drinking
Official Title OASIS - Orexin Receptor Antagonism for the Treatment of Alcohol Use Disorder and Stress-Related DrinkingPurpose
This study will look at whether suvorexant can help treat alcohol use disorder, how it works, and who it works best for. Suvorexant is a medicine that blocks certain brain signals linked to wakefulness.
Your total participation time in this study will be approximately 9 weeks.
Could this study be right for you?
Inclusion Criteria:
- Age 18-65
- Participant is able to give informed consent
- Engage in heavy alcohol use defined as drinking ≥14 standard drinks per week if male and ≥7 standard drinks per week if female.
General - Exclusion Criteria
- Clinically significant medical or neurological condition (e.g., liver disease, narcolepsy, complex sleep behaviors, severe hepatic impairment, COPD, severe obstructive sleep apnea)
- Current or past DSM-5 diagnosis of mania, schizophrenia, psychosis
- Past suicide attempt within 3 years or presence of moderate suicidal ideation
- Engage in night-shift work
Age Range
18 - 65 years -
Distressing Thoughts Study
Official Title Identification of novel signatures of proximal changes in the severity of suicide risk statesPurpose
This study will examine how people experience mental health symptoms, distress, and suicidal thoughts in their daily lives, to identify signs that indicate that someone's suicide risk is getting worse or improving. We will recruit people who are at different levels of suicide risk.
You will be asked to complete a survey about your life experiences, mental health symptoms, suicide thoughts, and coping strategies. You will also be asked to complete short surveys on your phones several times a day for 28 days to understand how suicide risk changes over time, and you will be provided with mental health resources you can access if in crisis.
Could this study be right for you?
- aged 18+
- the ability to speak, read, and understand English well enough to participate in study procedures
- comfort with smartphone technology
- are currently a U.S. resident
- participants must endorse suicidal ideation in the past week
- and/or endorse an suicide attempt, aborted attempt, or interrupted attempt within the past month
Age Range
18 - 100 years -
Pain Response Study in Autistic and Non-autistic Adults Ages 30-70.
Official Title Pain Sensitivity and Endogenous Pain Modulation in Autistic Adults (R21)Purpose
The purpose of this project is to study how pain may differ in adults with or without autism. Our goal is to study whether or not pain is experienced of felt differently in autistic adults compared to non-autistic adults.
Participants will be screened by phone. After meeting the initial screening criteria, the study visit will be scheduled. Participants can expect one study visit lasting 2-3 hours with time built in for breaks.
Could this study be right for you?
- Not currently on any daily pain medications
Age Range
30 - 70 years